A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

Part of paid clinical trials in Los Angeles, California.

Sponsor
Jazz Pharmaceuticals
Study ID
NCT07459634
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Extensive-stage Small-cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Lurbinectedin — DRUG
    Administered by intravenous (IV) infusion
  • Durvalumab — DRUG
    Administered by intravenous (IV) infusion

Study Details

The purpose of this study is to evaluate the efficacy and safety of lurbinectedin in combination with durvalumab for the treatment of participants with extensive stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first line (1L) induction therapy.

Key Dates

First listed
Mar 10, 2026
Start date
Aug 30, 2026
Status verified
Jul 2026
Primary completion
Jan 31, 2028
Completion
Apr 30, 2028

Study Design

Enrollment
50 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Durvalumab and lurbinectedin treatment arm
    Durvalumab taken in combination with lurbinectedin in participants with ES-SCLC after first line induction therapy with durvalumab and platinum plus etoposide containing regimen.

Primary Outcome Measure

Investigator assessed PFS rate [ Time Frame: 6 months ]

Central Contacts

Locations (4)

FacilityCityStateZIPSite coordinators
Valkyrie Clinical Trials, Inc.Los AngelesCalifornia90067-
Cancer Specialists of North FloridaJacksonvilleFlorida32256-
Emory UniversityAtlantaGeorgia30322-
Carolina Blood and Cancer CareRock HillSouth Carolina29732-

Find similar trials in Los Angeles, CA

By research site
Valkyrie Clinical Trials, Inc.· Los Angeles, CACancer Specialists of North Florida· Jacksonville, FLEmory University· Atlanta, GACarolina Blood and Cancer Care· Rock Hill, SC

Related Studies